EU, US Reviewers Differed On Ponvory’s Secondary Endpoints, But Hierarchy Didn’t Matter In The End
Executive Summary
Janssen went against EMA’s advice on the choice of secondary endpoints for its multiple sclerosis drug Ponvory (ponesimod), but still enjoyed a relatively brisk review. The hierarchical order of endpoints did not seem to ruffle any feathers among US FDA reviewers.
You may also be interested in...
Ponvory’s Regulatory Timeline At The US FDA And EMA
Janssen’s ponesimod for relapsing multiple sclerosis had a slightly faster review in the US.
English Reimbursement Win For Janssen’s Oral Multiple Sclerosis Drug
The health technology assessment body for England and Wales (NICE) has reversed its initial rejection of Ponvory, giving people with relapsing-remitting multiple sclerosis a new oral treatment option.
Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment
A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection.